DALLAS, April 8, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biopharmaceutical company Genta Inc. (OTCBB:GETA). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/GETA
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Genta Inc. (GETA) is a biopharmaceutical company engaged in research and development of novel drugs for the treatment of various cancers. The Company intends to commercialize its pharmaceutical technologies worldwide. The Company's drugs include Ganite® (gallium nitrate injection), Genasense® (oblimersen sodium) injection, Tesetaxel and oral gallium.
In the report, the analyst notes:
"Since its inception, the Company has incurred annual operating losses due to research and development, testing, production, logistics, regulatory and marketing costs relating to the Company's drug-candidate pipeline of drugs. Through December 31, 2009, the Company has accrued deficits of $1.03 billion, with further annual deficits expected until one or more of the Company's drug candidates achieves significant commercialization success.
"On April 6, the Company announced that it has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA) for the Company's Tesetaxel candidate drug compound developed for the treatment of patients afflicted with advanced gastric cancer."
To read the entire report visit: http://www.beaconequity.com/i/GETA
See what investors are saying about these stocks at penny stock forum.
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.